STING1 and familial pancreatic carcinoma: In summary, by harnessing the hyperactive immuno-stimulatory activity of the STINGR284S mutant and the delivery capability of mRNA-LNP, we have provided evidence for using the naturally occurring STINGR284S mutant as a novel therapeutic tool to reactivate the antitumor response in immunologically “cold” pancreatic cancer and in other STING-silenced tumors (Figure 7).